ERBB2 and breast cancer: In detail, the translational analysis of the Finher trial, which randomized 232 early HER2+ BC patients to receive either trastuzumab or no trastuzumab in combination with adjuvant chemotherapy, revealed a positive and significant association between increasing TILs and more favorable DDFS only in trastuzumab-treated patients, thus suggesting a possible predictive role of TILs in this regard [30].